Soft Tissue Sarcoma Treatment Market | Forecast 2018 to 2024
Soft Tissue Sarcoma Treatment Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024
Increment in the pervasiveness and frequency of various sorts of diseases, ascend in the quantity of delicate tissue sarcoma cases, increment in the R&D exercises on drugs and other organic treatments, patent expiry of marked medications, increment in the human services consumption and ascend in quality patient care are required to fuel the delicate tissue sarcoma treatment advertise over the gauge time frame. Be that as it may, high cost for the radiotherapy and chemotherapy, stringent administrative rules, and antagonistic impacts related with the treatment may ruin the development of delicate tissue sarcoma treatment showcase over the gauge time span.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-4H8Z4LpNMLEuOnnx
The soft tissue sarcoma treatment market has been segmented on basis of disease type, treatment type, and end user
Based on the treatment type, soft tissue sarcoma treatment market is segmented into following:
• Targeted Therapy
• Chemotherapy
• Anti-angiogenesis drugs
• Radiation Therapy
o Internal Radiation Therapy
o External Radiation Therapy
Based on the disease type, soft tissue sarcoma treatment market is segmented into following:
• Local Sarcoma
• Regional Sarcoma
• Metastatic Sarcoma
Based on the distribution channel, soft tissue sarcoma treatment market is segmented into following:
• Hospitals
• Oncology Clinics
• Long Term Care Centres
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-c654SbFYO64MsOhu
Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all evofosfamide development expenses. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/#ulp-14mlyhjMGhVjZqa3
Geographically, soft tissue sarcoma treatment market segmented into following regions Viz. North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America may lead the soft tissue sarcoma treatment market owing to increase in the prevalence of the disease. According to American Cancer Society, approximately 12,390 people in 2016 are suffering soft tissue sarcoma and cancer. Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. Asia-Pacific region accounts for a significant growth due to increase in cancer cases, and rise in awareness about advanced soft tissue sarcoma treatment.
Some of the players in the soft tissue sarcoma treatment market are GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) to name a few.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-soft-tissue-sarcoma-treatment-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com